Shikonin inhibits migration and invasion of triple-negative breast cancer cells by suppressing epithelial-mesenchymal transition via miR-17-5p/PTEN/Akt pathway

Conclusions: Shikonin inhibits migration and invasion of TNBC cells by suppressing EMT via miR-17-5p/PTEN/Akt pathway. This suggests shikonin as a promising therapeutic agent to counteract metastasis in the TNBC patients.

Source: Journal of Cancer - January 15, 2021 Category: Cancer & Oncology Authors: Chang Bao, Tao Liu, Lingbo Qian, Chi Xiao, Xinru Zhou, Heng Ai, Jue Wang, Weimin Fan, Jie Pan Tags: Research Paper Source Type: research